Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek held its 35th AGM on December 30, 2025, via video conferencing, with 36 members attending. The meeting ran for about 51 minutes (11:00 AM to 11:51 AM). Seven resolutions were tabled, including adoption of FY2024-25 audited financial statements, re-appointment of a rotating director, re-appointment of the Chairman & Managing Director and three Independent Directors for second terms, and appointment of Secretarial Auditors for a five-year period. Importantly, the Statutory Auditors and Secretarial Auditors both issued qualified opinions on the FY2024-25 reports, which were read out at the AGM as required. Voting was conducted via remote e-voting and Insta-Poll, with results to be declared within two working days.
The qualified audit opinions on FY2024-25 financials are a notable flag for investors and warrant attention to the scrutinizer's report once results are declared. Multiple director re-appointments (including the CMD and all three Independent Directors for second terms) indicate board continuity rather than change.